NCT00208312View on ClinicalTrials.gov

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

PHASE3CompletedINTERVENTIONAL
Enrollment

787

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Coronary Artery Disease
Interventions
DRUG

Regadenoson

0.4 mg, bolus intravenous injection

DRUG

Adenosine

0.14 mg/kg/min for 6 minutes, intravenous infusion

Trial Locations (1)

94304

Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Gilead Sciences

INDUSTRY